Article citationsMore>>

Irie, R.F., Ollila, D.W., O’Day, S. and Morton, D.L. (2004) Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma. Cancer Immunology, Immunotherapy, 53, 110- 117. doi:10.1007/s00262-003-0436-1

has been cited by the following article:

• TITLE: Recombinant IgM expression in mammalian cells: A target protein challenging biotechnological production

  AUTHORS: Alexander Mader, Veronika Chromikova, Renate Kunert

  KEYWORDS: IgM; Mammalian Expression; Recombinant Antibody Expression; Antibody Purification

  JOURNAL NAME: Advances in Bioscience and Biotechnology, Vol.4 No.4A, April 30, 2013

  ABSTRACT: For many years, the potential of immunoglobulin M (IgM) antibodies was not fully understood because of characteristics different to the well-known immunoglobulin G type like low target affinity, cross reactivity and complex protein structure. In the meanwhile IgMs have been positively evaluated for their use as therapeutic agent in the mucosal environment but also in serum to eradicate upcoming tumor cells and invading antigens. Therefore IgM class of antibodies will play a significant role in clinical applications but also diagnosis in the future. To evaluate the full potential of this kind of antibody molecules large amounts of high quality product will be needed. In this review the focus is set on the biotechnological aspect of producing IgM class antibodies recombinantly in mammalian cells. Current achievements in expression and purification of this molecule are highlighted and compared.